lab testing – Share Talk

Genedrive PLC (AIM:GDR) US FDA pre-submission for Genedrive MT-RNR1 kit

Abm October 5, 2022

Genedrive file US FDA Pre-Submission for the Genedrive ® MT-RNR1 Product Range

Genedrive PLC (AIM:GDR) NICE includes Genedrive CYP2C19-ID Kit in new Diagnostics Assessment Programme

Abm August 22, 2022

genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces that the UK’s National Institute for Health and Clinical Excellence (‘NICE’) has commenced an evaluation of CYP2C19 genotype testing for

Genedrive PLC (AIM:GDR) Point-of-Care COV19-ID Kit receives CTDA approval

Abm May 30, 2022

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK Medicines and Healthcare Products Regulatory Agency has granted a CTDA enabling the sale of the Genedrive®

Genedrive PLC (AIM:GDR) NICE issues Medtech Innovation Briefing

Abm March 29, 2022

NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test

Genedrive® MT-RNR1 ID Kit Product – Video

Abm March 25, 2022

World’s first point of care genetic test used to influence neonatal management in an acute setting and reduce aminoglycoside-induced hearing loss

Genedrive PLC (AIM:GDR) First NHS Deployments of Genedrive System for AIHL

Abm March 18, 2022

First NHS Deployments of the Genedrive® System for Antibiotic Induced Hearing Loss

Genedrive PLC (AIM: GDR) Update on Point of Care Covid Test

Abm February 23, 2022

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, provides an update on the progress being made on the Genedrive®COV19-ID kit, its rapid point of care molecular test for